Next Article in Journal / Special Issue
Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
Previous Article in Journal
Identification of Mycoses in Developing Countries
Previous Article in Special Issue
Hospital Laboratory Survey for Identification of Candida auris in Belgium
Open AccessCase Report

The First Two Cases of Candida auris in The Netherlands

Department of Medical Microbiology and Infection Control, Amsterdam UMC, location VUmc, 1081 HV Amsterdam, The Netherlands
Department of Medical Microbiology and Immunology, Meander Medical Center, 3813 TZ Amersfoort, The Netherlands
Mycotic Diseases Branch, Division of Foodborne, Waterborne and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital (CWZ), 6532 SZ Nijmegen, The Netherlands
Centre of Expertise in Mycology, Radboudumc/CWZ, 6532 SZ Nijmegen, The Netherlands
Author to whom correspondence should be addressed.
J. Fungi 2019, 5(4), 91;
Received: 29 August 2019 / Revised: 16 September 2019 / Accepted: 24 September 2019 / Published: 30 September 2019
(This article belongs to the Special Issue Candida auris)
Candida auris is a rapidly emerging multidrug-resistant pathogenic yeast. In recent years, an increasing number of C. auris invasive infections and colonized patients have been reported, and C. auris has been associated with hospital outbreaks worldwide, mainly in intensive care units (ICUs). Here, we describe the first two cases of C. auris in The Netherlands. Both cases were treated in a healthcare facility in India prior to admission. The patients were routinely placed in contact precautions in a single room after admission, which is common practice in The Netherlands for patients with hospitalization outside The Netherlands. No transmission of C. auris was noticed in both hospitals. Routine admission screening both for multidrug-resistant (MDR) bacteria and MDR yeasts should be considered for patients admitted from foreign hospitals or countries with reported C. auris transmission. View Full-Text
Keywords: Candida auris; emergence; molecular typing; infection prevention Candida auris; emergence; molecular typing; infection prevention
Show Figures

Figure 1

MDPI and ACS Style

Vogelzang, E.H.; Weersink, A.J.; van Mansfeld, R.; Chow, N.A.; Meis, J.F.; van Dijk, K. The First Two Cases of Candida auris in The Netherlands. J. Fungi 2019, 5, 91.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop